Phase I Study Of IDEC-152 (Anti-CD23 Monoclonal Antibody) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2009
At a glance
- Drugs Lumiliximab (Primary)
- Indications Chronic lymphocytic leukaemia; Lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2005 New trial record.